"Heartland Hematology and Oncology offers the latest in lifesaving hematology-oncology services to the newest technology in cancer treatment. Patients can take advantage of innovative therapies in a community practice setting."

During the past decade, Heartland Hematology and Oncology conducted 77 clinical trials. In the 10-year time frame, 77 clinical trials started and 44 clinical trials were completed, i.e. on average, 57.1% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 41 clinical trials were completed. i.e. 683.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Heartland Hematology and Oncology" #1 sponsor was "National Cancer Institute (NCI)" with 49 trials, followed by "SWOG Cancer Research Network" with 24 trials sponsored, "Alliance for Clinical Trials in Oncology" with 13 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 8 trials sponsored and "Children's Oncology Group" with 8 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Heartland Hematology and Oncology" #1 collaborator was "National Cancer Institute (NCI)" with 52 trials as a collaborator, "NRG Oncology" with 13 trials as a collaborator, "Canadian Cancer Trials Group" with 5 trials as a collaborator, "Agenus Inc." with 1 trials as a collaborator and "Bayer" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Heartland Hematology and Oncology" are "Recurrent Squamous Cell Lung Carcinoma" (7 trials), "Recurrent Ovarian Carcinoma" (6 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (6 trials), "Recurrent Breast Carcinoma" (5 trials) and "Recurrent Fallopian Tube Carcinoma" (4 trials). Many other conditions were trialed in "Heartland Hematology and Oncology" in a lesser frequency.

Most popular intervention types in "Heartland Hematology and Oncology" are "Drug" (78 trials), "Other" (70 trials), "Biological" (45 trials), "Procedure" (24 trials) and "Radiation" (7 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (44 trials), "Quality-of-Life Assessment" (22 trials), "Nivolumab" (15 trials), "Cisplatin" (13 trials) and "Carboplatin" (12 trials). Other intervention names were less common.

The vast majority of trials in "Heartland Hematology and Oncology" are 79 trials for "All" genders, 21 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Heartland Hematology and Oncology". undefined are not yet recruiting, 15 are recruiting, 62 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Heartland Hematology and Oncology, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Heartland Hematology and Oncology, 3 "Phase 1" clinical trials were conducted, 51 "Phase 2" clinical trials and 49 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".